Kurt J. Hilzinger - Oct 1, 2024 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role
Director
Signature
/s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol
OTLK
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
4
Date filed
10/3/2024, 08:30 PM
Previous filing
Oct 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLK Stock Option (Right to Buy) Award $0 +56.6K $0.00 56.6K Oct 1, 2024 Common Stock 56.6K $5.22 Direct F1
transaction OTLK Stock Option (Right to Buy) Award $0 +105K $0.00 105K Oct 1, 2024 Common Stock 105K $5.22 Direct F2
transaction OTLK Stock Option (Right to Buy) Award $0 +18.7K $0.00 18.7K Oct 3, 2024 Common Stock 18.7K $5.25 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
F2 This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
F3 The options were granted under the 2024 Plan in lieu of $85,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.